Evidence map›Paper›PMID 37606752›Full record

ArticleBiotechnology letters2023

Simple chitin-based cell culture platform for production of biopharmaceuticals.

Katsuhiko Kida, Daisuke Hatanaka, Masataka Minami, Taiyo Suzuki, Masashi Iwakami, Masaki Kobayashi, Hisato Hayashi, Hiroharu Kawahara, Masato Horikawa, Tatsuro Kanaki

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Katsuhiko KidaBiological Research Laboratories, Nissan Chemical Corporation, Saitama, Japan. kidak@nissanchem.co.jp.ORCID http://orcid.org/0000-0003-2956-0784
Daisuke HatanakaMaterials Research Laboratories, Nissan Chemical Corporation, Chiba, Japan.
Masataka MinamiMaterials Research Laboratories, Nissan Chemical Corporation, Chiba, Japan.
Taiyo SuzukiMaterials Research Laboratories, Nissan Chemical Corporation, Chiba, Japan.
Masashi IwakamiBiological Research Laboratories, Nissan Chemical Corporation, Saitama, Japan.
Masaki KobayashiBiological Research Laboratories, Nissan Chemical Corporation, Saitama, Japan.
Hisato HayashiHead office, Nissan Chemical Corporation, Tokyo, Japan.
Hiroharu KawaharaDepartment of Creative Engineering, Material Chemistry Course, National Institute of Technology Kitakyushu College, Fukuoka, Japan.
Masato HorikawaHead office, Nissan Chemical Corporation, Tokyo, Japan.
Tatsuro KanakiHead office, Nissan Chemical Corporation, Tokyo, Japan.
Nissan Chemical Corporation (Japan) · JPKitakyushu National College of Technology · JPNissan (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGene therapy using viral vectors and antibody-based therapies continue to expand within the pharmaceutical market. We evaluated whether Cellhesion

resultsThe results of Cell Counting Kit-8 assay and LDH assay revealed that Cellhesion

conclusionsCellhesion

Indexed as

Biological ProductsAnimalsCell Culture TechniquesChitinCHO CellsCricetinaeCricetulusHEK293 CellsHumansBiological ProductsChitin3D cell cultureBiopharmaceuticalsChitinContinuous manufacturingScale-up culture

Identifiers

PMID37606752
OpenAlexW4386046300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.